Clinically validated genotype analysis: Guiding principles and statistical concerns

Antiviral Therapy

Volumn 9, Issue 4, 2004, Pages 465-478

  Brun Vézinet, Françoise ^a   Costagliola, Dominique ^b   Ait Khaled, Mounir ^c   Calvez, Vincent ^d   Clavel, François ^a   Clotet, Bonaventura ^e   Haubrich, Richard ^f   Kempf, Dale ^g   King, Marty ^g   Kuritzkes, Daniel ^h   Lanier, Randall ⁱ   Miller, Michael ^j   Miller, Veronica ^k   Phillips, Andrews ^l   Pillay, Deenan ^m   Schapiro, Jonathan ⁿ   Scott, Janna ⁱ   Shafer, Robert ^o   Zazzi, Maurizio ^p   Zolopa, Andrew ^o   DeGruttola, Victor ^q   more..

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c GLAXOSMITHKLINE   (United Kingdom)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Fundacio IrsiCaix ^*  (Spain)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ABBOTT LABORATORIES   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j GILEAD SCIENCES   (United States)

^k DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁿ AIDS Serv Natl Hemophilia Centre   (Israel)

^o STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^p UNIVERSITY OF SIENA   (Italy)

^q HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; LOPINAVIR; RITONAVIR; TENOFOVIR;

ADD ON THERAPY; ANALYTIC METHOD; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; ROC CURVE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VALIDATION PROCESS; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MUTATION; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; ROC CURVE;

EID: 4344701042     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP & Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-93.
2. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R & De Luca A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-379.
3. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AJ, Graham NM & the VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-588.
4. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199.
5. Meynard J-L, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F & Girard P-M. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
6. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, Domingo P, Boucher C, Rey-Joly C, Clotet B & the Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
7. Haubrich R, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, Leibowitz M, Hwang J, Seefried E, McCutchan JA, Hellmann N, Richman D & the CCTG Study Team. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antiviral Therapy 2001; 6(Suppl. 1):63.
8. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peter B, Phillips A, Pillay D, Wilkins E, Williams I & Youle M. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2003; 4(Suppl. 1):1-41.
9. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases 2003; 37:113-128.
10. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288:222-235.
11. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. www.aidsinfo.nih.gov (10 November 2003).
12. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R & Rizzo C. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. Journal of Virology 2001; 75:4999-5008.
13. Falloon J, Ait-Khaled M, Thomas DA, Brosgart CL, Eron Jr JJ, Feinberg J, Flanigan TP, Hammer SM, Kraus PW, Murphy R, Torres R & Masur H. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 2002; 16:387-396.
14. Lecossier D, Shulman N, Zolopa AR, Clavel F & Hance AJ. Resistance genotypes in patients failing nevirapine: coexistence of majority viral populations expressing Y181C and minority populations expressing K103N. Antiviral Therapy 2003; 8:S159.
15. Lanier ER, Ait-Khaled M, Scott J, Stone C, Melby T, Sturge G, St Clair M, Steel H, Hetherington S, Pearce G, Spreen W & Lafon S. Antiviral efficiacy of abacavir in antiretroviral therapy experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antiviral Therapy 2004; 9:37-45.
16. Tisdale M, Alnadaf T & Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents & Chemotherapy 1997; 41:1094-1098.
17. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R & Larder BA. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671-1677.
18. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C & Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 2004; 48:437-443.
19. Lu B, Hellmann NS, Bates M, Dawson K, Rooney J & Miller MD. Determination of clinical cut-offs for reduced response to tenofovir DF therapy in antiretroviral-experienced patients. Antiviral Therapy 2002; 7:S104-S105. Abstract 125.
20. Descamps D, Masquelier B, Mamet JP, Calvez V, Ruffault A, Telles F, Goetschel A, Girard PM, Brun-Vézinet F & Costagliola D. A genotypic sensitivity score for amprenavir based on genotype at baseline and virological response. Antiviral Therapy 2001; 6(Suppl. 1):103.
21. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E & Rode RA. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Journal of Virology 2001; 75:7462-7469.
22. Kempf D, Brun S, Rode R, Isaacson J, King M, Xu Y, Real K, Hsu A, Granneman R, Lie Y, Hellmann N, Bernstein B & Sun E. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naive patients. Antiviral Therapy 2000; 5(Suppl. 3):70-71.
23. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R & Sun E. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antiviral Therapy 2002; 7:165-174.
24. Isaacson J, Kempf D, Calvez V, Cohen-Codar I, Descamps D, Guillevic E, Bernstein B, Sun E, Chauvin JP, Rode R & Grebner K. Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients. 9th Conference on Retroviruses & Opportunistic Infections, 24-28 February 2002, Seattle, Wash., USA. Abstract 559-T.
25. Molina JM, Marcelin AG, Pavie J, Merle C, Troccaz M, Leleu G & Calvez V. Didanosine in HIV-infected patients; results from a randomized double-blind study (A1454-176 Jaguar). 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy, 14-17 February 2003, Chicago, Ill., USA. Abstract H-447.
26. Miller MD, Zhong L, Chen S, Margot NA & Wulfsohn W. Multivariate analyses of antiviral response to tenofovir DF therapy in antiretroviral- experienced patients. Antiviral Therapy 2002; 7:S16. Abstract 14.
27. Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard J-L, Vray M, Costagliola D & Narval (ANRS 088) Study Group. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003; 17:1795-1802.
28. Costagliola D, Descamps D, Calvez V, Masquelier B, Ruffault A, Telles F, Meynard J-L & Brun-Vézinet F. Presence of thymidine analogs mutations and virologic response to nucleoside reverse transcriptase inhibitors. Antiviral Therapy 2001; 6:S8. Abstract 7.
29. Masquelier B, Tamalet C, Montès B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferré V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vézinet F, Costagliola D & the ANRS AC11 Resistance Study Group. Genotypic determinants of the virological response to tenofovir DF in NRTI-experienced patients. Antiviral Therapy 2004; 9:315-323.
30. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropoulos C & Whitcomb J. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001; 15:1125-1132.
31. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D & McCutchan JA. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33-F40.
32. Wirden M, Simon A, Schneider L, Tubiana R, Paris L, Marcelin AG, Delaugerre C, Legrand M, Herson S, Peytavin G, Katlama C & Calvez V. Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations asociated with resistance to NNRTIs. Journal of Clinical Microbiology 2003; 41:2713-2715.
33. Maldarelli F, Palmer S, Kearney M, Falloon J, Davey RT, Powers A, Vogel S, Pau A, Dewar R, Metcalf RT, Mellors J & Coffin J. Short duration, single drug discontinuation to assess the activity of individual drugs in patients failing antiretroviral therapy. Antiviral Therapy 2003; 8:S149. Abstract 133.
34. Campbell TB, Young RK, Johnson SC, Lanier ER & Kuritzkes DR. Antiviral activity of lamivudine in persons infected with HIV-1 that has M184V and multiple thymidine analogue mutations. Antiviral Therapy 2003; 8:S156. Abstract 140.
35. Breiman, L, Stone CJ, Olshen RA & Freidman JH. Classification and Regression Trees. 1984; Belmont, Calif.: Wadsworth.
36. Geladi P & Kowalski B. Partial least squares regression: a tutorial. Analytica Chimica Acta 1986; 185:1-17.
37. Wang D, DeGruttola V, Hammer S, Harrigan R, Larder B, Wegner S, Winslow D & Zazzi M. A collaborative HIV resistance response database initiative: predicting virological response using neural network models. Antiviral Therapy 2002; 7:S96-S97. Abstract 119.
38. Wang D, Larder BA, Revell A, Harrigan R & Montaner J. A neural network model using clinical cohort data accurately predicts virological response and identifies regimens with increased probability of success in treatment failures. Antiviral Therapy 2003; 8:S112. Abstract 102.
39. Lanier ER, Scott J, Ait-Khaled M, Stone C, Melby T, Sturge G, Steel H, Hetherington S, Pearce G, Spreen W & Lafon S. Predicting abacavir antiviral activity using HIV-1 reverse transcriptase genotype: a comparison of 12 algorithms. Antiviral Therapy 2001; 6(Suppl. 1):103-104.
40. Reid C, Bassett R, Day S, Larder B, DeGruttola V & Winslow D. A dynamic rules-based interpretation system derived by an expert panel is predictive of virological failure. Antiviral Therapy 2002; 7:S91-S92. Abstract 112.
41. King M, Kempf D, Isaacson J, Rode R, Brun S, Bernstein B, Calvez V, Cohen-Codar I, Gullevic E, Chauvin JP & Sun E. Using classification trees to explore relationships between viral genotype and response to lopinavir/ritonavir-based regimens. Antiviral Therapy 2002; 7:S82-83. Abstract 100.
42. Parkin NT, Chappey C, Petropoulos CJ & Hellmann N. HIV-1 reverse transcriptase mutations other than M184I/V that suppress zidovudine resistance also increase in vitro susceptibility to tenofovir, but not stavudine. Antiviral Therapy 2003; 8:S34. Abstract 29.
43. Harrell FE, Lee KL, Matchar DB & Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treatment Reports 1985; 69:1071-1077.
44. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR & Sun E. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy 2003; 47:350-359.
45. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ & Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. Journal of Infectious Diseases 2002; 185:599-607.
46. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z & Lundgren JD. Randomized trial to evaluate indinavir/ ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCMin1 trial. Journal of Infections Diseases 2003; 188:635-642.
47. Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G & Vilde JL. Amprenavir inhibitory qoutient and virological response in human immunodeficiency virus-infected patients on amprenavir-containing salvage regimen without or with ritonavir. Antimicrobial Agents & Chemotherapy 2002; 46:570-574.
48. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ & Sun E. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrobial Agents & Chemotherapy 2002; 46:3907-3916.
49. Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH & Mayers DL. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 2002; 16:1131-1138.
50. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait MH, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G & Calvez V. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrobial Agents & Chemotherapy 2003; 47:594-600.
51. Marcelin AG, Lamotte C, Ait Mohand H, Delaugerre C, Ktorza N, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G & Calvez V. Efficacy of ritonavir/amprenavir containing regimen in HIV-1 protease inhibitor experienced patients and predictivity of the delta viral load values up to week 24 using genotypic inhibitory quotient. Antiviral Therapy 2003; 8(Suppl. 1):S225.
52. Marcelin AG, Cohen-Codar I, King M, Guillevic E, Lamotte C, Chauvin JP, Kempf D, Peytavin G & Calvez V. Virological and pharmacological factors predicting the response to LPV/r. Antiviral Therapy 2004; 8(Suppl. 1):S416-S417.
53. Bacheler L, Vermeiren H, McKenna P, Van Houtte M & Lecocq P. Trends in genotypic and phenotypic resistance among clinical samples submitted for routine HIV resistance analysis. Antiviral Therapy 2003; 8:S132. Abstract 118.
54. Lanier ER, Scott J, Ait-Khaled M, Craig C, Alcorn T, Irlbeck D, Gerondelis P, Burgess R & Underwood M. Prevalence of mutations associated with resistance to antiretroviral therapy from 1999-2002. 10th Conference on Retroviruses & Opportunistic Infections, 10-14 February 2003, Boston, Mass., USA. Abstract 635.
55. Parikh U, Koontz D, Hammond J, Bacheler L, Schinazi R, Meyer P, Scott W & Mellors J. K65R: a multi-nucleoside resistance mutation of low but increasing frequency. Antiviral Therapy 2003; 8:S152. Abstract 136.
56. Winston A, Pozniak A, Gazzard B & Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase? Antiviral Therapy 2003; 8:S153. Abstract 137.
57. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulatto AS, Lamy PD, Margot NA, Anton KE & Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4:87-94.
58. Winters MA, Schafer RW, Jellinger RA, Mamtora G, Gingeras T & Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrobial Agents & Chemotherapy 1997; 41:757-762.
59. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G & Tisdale M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000; 14:163-171.